These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8411019)

  • 1. Hydroxylated 2-(5'-salicyl)naphthalenes as protein-tyrosine kinase inhibitors.
    Smyth MS; Stefanova I; Horak ID; Burke TR
    J Med Chem; 1993 Oct; 36(20):3015-20. PubMed ID: 8411019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors.
    Smyth MS; Stefanova I; Hartmann F; Horak ID; Osherov N; Levitzki A; Burke TR
    J Med Chem; 1993 Oct; 36(20):3010-4. PubMed ID: 8105084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p56lck.
    Burke TR; Lim B; Marquez VE; Li ZH; Bolen JB; Stefanova I; Horak ID
    J Med Chem; 1993 Feb; 36(4):425-32. PubMed ID: 8474097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol.
    Thakkar K; Geahlen RL; Cushman M
    J Med Chem; 1993 Oct; 36(20):2950-5. PubMed ID: 8411012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of styryl-based inhibitors of the lymphocyte tyrosine protein kinase p56lck.
    Li ZH; Burke TR; Bolen JB
    Biochem Biophys Res Commun; 1991 Oct; 180(2):1048-56. PubMed ID: 1659394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of hydroxylated flavones and related compounds as potential inhibitors of the protein-tyrosine kinase p56lck.
    Cushman M; Nagarathnam D; Geahlen RL
    J Nat Prod; 1991; 54(5):1345-52. PubMed ID: 1800636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships in a series of 5-[(2,5-dihydroxybenzyl)amino]salicylate inhibitors of EGF-receptor-associated tyrosine kinase: importance of additional hydrophobic aromatic interactions.
    Chen H; Boiziau J; Parker F; Mailliet P; Commerçon A; Tocque B; Le Pecq JB; Roques BP; Garbay C
    J Med Chem; 1994 Mar; 37(6):845-59. PubMed ID: 8145236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors. 2. Synthesis of 2,2'-dithiobis(1H-indole-3-alkanamides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases.
    Thompson AM; Fry DW; Kraker AJ; Denny WA
    J Med Chem; 1994 Mar; 37(5):598-609. PubMed ID: 7510340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors.
    Burke TR; Barchi JJ; George C; Wolf G; Shoelson SE; Yan X
    J Med Chem; 1995 Apr; 38(8):1386-96. PubMed ID: 7537333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases.
    Livolsi A; Busuttil V; Imbert V; Abraham RT; Peyron JF
    Eur J Biochem; 2001 Mar; 268(5):1508-15. PubMed ID: 11231305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity.
    Faltynek CR; Schroeder J; Mauvais P; Miller D; Wang S; Murphy D; Lehr R; Kelley M; Maycock A; Michne W
    Biochemistry; 1995 Sep; 34(38):12404-10. PubMed ID: 7547985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyr394 and Tyr505 are autophosphorylated in recombinant Lck protein-tyrosine kinase expressed in Escherichia coli.
    Jullien P; Bougeret C; Camoin L; Bodeus M; Durand H; Disanto JP; Fischer S; Benarous R
    Eur J Biochem; 1994 Sep; 224(2):589-96. PubMed ID: 7523116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naphthyl ketones: a new class of Janus kinase 3 inhibitors.
    Brown GR; Bamford AM; Bowyer J; James DS; Rankine N; Tang E; Torr V; Culbert EJ
    Bioorg Med Chem Lett; 2000 Mar; 10(6):575-9. PubMed ID: 10741557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of the SH2 domain of lymphocyte-specific tyrosine protein kinase p56lck with phosphotyrosine-containing proteins.
    Peri KG; Gervais FG; Weil R; Davidson D; Gish GD; Veillette A
    Oncogene; 1993 Oct; 8(10):2765-72. PubMed ID: 7690927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naphthalene combretastatin analogues: synthesis, cytotoxicity and antitubulin activity.
    Medarde M; Maya AB; Pérez-Melero C
    J Enzyme Inhib Med Chem; 2004 Dec; 19(6):521-40. PubMed ID: 15662956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the enzymatic function of the lymphocyte-specific tyrosine protein kinase p56lck by the non-catalytic SH2 and SH3 domains.
    Veillette A; Caron L; Fournel M; Pawson T
    Oncogene; 1992 May; 7(5):971-80. PubMed ID: 1570157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redox regulation of a src family protein tyrosine kinase p56lck in T cells.
    Nakamura K; Hori T; Sato N; Sugie K; Kawakami T; Yodoi J
    Oncogene; 1993 Nov; 8(11):3133-9. PubMed ID: 8414515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.